Diagnosis and treatment of primary aldosteronism

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 313-332

  Rossi, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Aldosterone; Arterial hypertension; Diagnosis; Primary aldosteronism

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM DERIVATIVE; SPIRONOLACTONE;

ADRENAL CORTEX ADENOMA; ADRENAL PHLEBOGRAPHY; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DNA DAMAGE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH CARE PLANNING; HUMAN; HYPERTENSION; HYPOKALEMIA; PATIENT ASSESSMENT; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SALT LOADING; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; MASS SCREENING; PREVALENCE;

EID: 79955733901     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.01.005     Document Type: Review

References (122)

1. Kucharz E.J. Forgotten description of primary hyperaldosteronism. Lancet 1991, 337:1490.
2. Conn J.W. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:3-17.
3. Conn J.W., Knopf R.F., Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964, 107:159-172.
4. Rossi G.P. Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2006, 20:385-400.
5. Fritsch N.M., Schiffrin E.L. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 2003, 5:59-65.
6. Pu Q., Neves M.F., Virdis A., et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003, 42:49-55.
7. Schupp N., Queisser N., Wolf M., et al. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm Metab Res 2010, 42(6):458-465.
8. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810.
9. Brilla C.G., Maisch B., Weber K.T. Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J 1992, 13(Suppl D):24-32.
10. Brilla C.G., Pick R., Tan L.B., et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355-1364.
11. Rossi G.P., Sacchetto A., Pavan E., et al. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertens 1997, 19(Suppl 8):S147-S151.
12. Rossi G.P., Sacchetto A., Pavan E., et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997, 95:1471-1478.
13. Rossi G.P., Di Bello V., Ganzaroli C., et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002, 40:23-27.
14. Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103:425-431.
15. Nishizaka M.K., Zaman M.A., Green S.A., et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857-2861.
16. Taddei S., Virdis A., Mattei P., et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21:929-933.
17. Muiesan M.L., Rizzoni D., Salvetti M., et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002, 20:1439-1444.
18. Rizzoni D., Muiesan M.L., Porteri E., et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998, 32:985-992.
19. Halimi J.M., Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995, 13:1801-1802.
20. Rossi G.P., Bernini G., Desideri G., et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006, 48:232-238.
21. Rossi G.P., Sechi L.A., Giacchetti G., et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008, 19:88-90.
22. Sechi L.A., Novello M., Lapenna R., et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006, 295:2638-2645.
23. Nishimura M., Uzu T., Fujii T., et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999, 33:261-266.
24. Takeda R., Matsubara T., Miyamori I., et al. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995, 18:370-373.
25. Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
26. Sawka A.M., Young W.F., Thompson G.B., et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258-261.
27. Rossi G.P., Bolognesi M., Rizzoni D., et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008, 51:1366-1371.
28. Catena C., Colussi G., Lapenna R., et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007, 50:911-918.
29. Conn J.W. Primary aldosteronism. Hypertension: pathophysiology and treatment 1977, McGraw-Hill, New York.
30. Conn J.W. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1990, 116:253-267.
31. Conn J.W. Plasma renin activity in primary aldosteronism. JAMA 1964, 190:222-225.
32. Conn J.W. A concluding response. Arch Intern Med 1969, 123:154-155.
33. Rossi G.P. Primary aldosteronism: a needle in a haystack or a yellow cab on fifth avenue?. Curr Hypertens Rep 2004, 6:1-4.
34. Rossi G.P., Pessina A.C., Heagerty A.M. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens 2008, 26:613-621.
35. Gordon R.D., Ziesak M.D., Tunny T.J., et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296-298.
36. Anderson G.H., Blakeman N., Streeten D.H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994, 12:609-615.
37. Gordon R.D., Stowasser M., Tunny T.J., et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
38. Abdelhamid S., Muller-Lobeck H., Pahl S., et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med 1996, 156:1190-1195.
39. Brown M.A., Cramp H.A., Zammit V.C., et al. Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'?. Aust N Z J Med 1996, 26:533-538.
40. Rossi G.P., Rossi E., Pavan E., et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998, 49:713-723.
41. Mosso L., Fardella C., Montero J., et al. Rev Med Chil 1999, 127:800-806. [in Spanish].
42. Rayner B.L., Opie L.H., Davidson J.S. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394-400.
43. Loh K.C., Koay E.S., Khaw M.C., et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000, 85:2854-2859.
44. Denolle T., Hanon O., Mounier-Vehier C., et al. Arch Mal Coeur Vaiss 2000, 93:1037-1039. [in French].
45. Cortes P., Fardella C., Oestreicher E., et al. Rev Med Chil 2000, 128:955-961. [in Spanish].
46. Nishikawa T., Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai hospital. Biomed Pharmacother 2000, 54(Suppl 1):83s-85s.
47. Fardella C.E., Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
48. Lim P.O., Dow E., Brennan G., et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 14:311-315.
49. Rayner B.L., Myers J.E., Opie L.H., et al. Screening for primary aldosteronism-normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001, 91:594-599.
50. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
51. Schwartz G.L., Chapman A.B., Boerwinkle E., et al. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002, 48:1919-1923.
52. Rossi E., Regolisti G., Negro A., et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002, 15:896-902.
53. Rossi G.P., Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
54. Rossi G.P., Seccia T.M., Pessina A.C. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci 2007, 44:1-85.
55. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
56. Goodfriend T.L., Calhoun D.A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004, 43:518-524.
57. Rossi G.P., Belfiore A., Bernini G., et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008, 93(7):2566-2571.
58. Hiramatsu K., Yamada T., Yukimura Y., et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981, 141:1589-1593.
59. Mulatero P., Dluhy R.G., Giacchetti G., et al. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005, 16:114-119.
60. Sealey J.E. Plasma renin activity and plasma prorenin assays. Clin Chem 1991, 37:1811-1819.
61. Roding J.H., Weterings T., van der Heiden C. Plasma renin activity: temperature optimum at approximately 45 degrees C. Clin Chem 1997, 43:1243-1244.
62. Sealey J.E., Gordon R.D., Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005, 16:86-91.
63. Campbell D.J., Nussberger J., Stowasser M., et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009, 55:867-877.
64. Rossi G.P., Barisa M., Belfiore A., et al. The aldosterone renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010, 28(9):1892-1899.
65. Mulatero P., Rabbia F., Milan A., et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002, 40:897-902.
66. Stowasser M., Gordon R.D., Rutherford J.C., et al. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001, 2:156-169.
67. Stowasser M., Gordon R.D., Gunasekera T.G., et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003, 21:2149-2157.
68. Giacchetti G., Ronconi V., Lucarelli G., et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006, 24:737-745.
69. Rossi G.P., Seccia T.M., Palumbo G., et al. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension 2010, 55:83-89.
70. Agharazii M., Douville P., Grose J.H., et al. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001, 37:1440-1443.
71. Castro O.L., Yu X., Kem D.C. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension 2002, 39:935-938.
72. Irony I., Kater C.E., Biglieri E.G., et al. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990, 3:576-582.
73. Gordon R.D., Gomez-Sanchez C.E., Hamlet S.M., et al. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA:adrenal hyperplasia) or low-renin hypertension. J Hypertens Suppl 1987, 5(Suppl 5):S103-S106.
74. Holland O.B., Brown H., Kuhnert L., et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984, 6:717-723.
75. Rossi G.P., Belfiore A., Bernini G., et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007, 50:424-431.
76. Gordon R.D. Primary aldosteronism. J Endocrinol Invest 1995, 18:495-511.
77. Mulatero P., Stowasser M., Loh K.C., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004, 89:1045-1050.
78. Goh B.K., Tan Y.H., Chang K.T., et al. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J Surg 2007, 31:72-79.
79. Rossi G.P., Chiesura-Corona M., Tregnaghi A., et al. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens 1993, 7:357-363.
80. Rossi G.P., Vendraminelli R., Cesari M., et al. A thoracic mass with hypertension and hypokalaemia. Lancet 2000, 356:1570.
81. Seccia T.M., Fassina A., Nussdorfer G.G., et al. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005, 12:149-159.
82. Omura M., Sasano H., Fujiwara T., et al. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002, 51:350-355.
83. Fallo F., Barzon L., Boscaro M., et al. Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism. Am J Hypertens 1997, 10:476-478.
84. Magill S.B., Raff H., Shaker J.L., et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001, 86:1066-1071.
85. Mantero F., Terzolo M., Arnaldi G., et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000, 85:637-644.
86. Young W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136:1227-1235.
87. Kempers M.J., Lenders J.W., van Outheusden L., et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009, 151:329-337.
88. Stewart P.M., Allolio B. Adrenal vein sampling for primary aldosteronism: time for a reality check. Clin Endocrinol (Oxf) 2010, 72:146-148.
89. Rossi G.P., Pitter G., Bernante P., et al. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008, 26:989-997.
90. Stowasser M., Gordon R.D. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol 2004, 217:33-39.
91. Rossi G.P., Ganzaroli C., Miotto D., et al. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 2006, 24:371-379.
92. Seccia T.M., Miotto D., De Toni R., et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 2009, 53:761-766.
93. Rossi G.P., Sacchetto A., Chiesura-Corona M., et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001, 86:1083-1090.
94. Rossi G.P. New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism. Curr Hypertens Rep 2007, 9:90-97.
95. Mulatero P., Bertello C., Sukor N., et al. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension 2010, 55:667-673.
96. Young W.F., Stanson A.W. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?. Clin Endocrinol (Oxf) 2009, 70:14-17.
97. Letavernier E., Peyrard S., Amar L., et al. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008, 26:1816-1823.
98. Mulatero P., Bertello C., Rossato D., et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008, 93:1366-1371.
99. Sukor N., Gordon R.D., Ku Y.K., et al. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009, 94:2437-2445.
100. Harvey A., Kline G., Pasieka J.L. Adrenal venous sampling in primary hyperaldosteronism: comparison of radiographic with biochemical success and the clinical decision-making with " less than ideal" testing. Surgery 2006, 140:847-853.
101. Auchus R.J., Wians F.H., Anderson M.E., et al. What we still do not know about adrenal vein sampling for primary aldosteronism. Horm Metab Res 2010, 42:411-415.
102. Miotto D., De Toni R., Pitter G., et al. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 2009, 54:885-889.
103. Mengozzi G., Rossato D., Bertello C., et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 2007, 53:1968-1971.
104. Auchus R.J., Michaelis C., Wians F.H., et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009, 249:318-321.
105. Carr C.E., Cope C., Cohen D.L., et al. Comparison of sequential versus simultaneous methods of adrenal venous sampling. J Vasc Interv Radiol 2004, 15:1245-1250.
106. Shade R.E., Grim C.E. Suppression of renin and aldosterone by small amounts of DOCA in normal man. J Clin Endocrinol Metab 1975, 40:652-658.
107. Enberg U., Volpe C., Hoog A., et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur J Endocrinol 2004, 151:73-85.
108. Nishimoto K., Nakagawa K., Li D., et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab 2010, 95:2296-2305.
109. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005, 25(Suppl 1):S143-S158.
110. Mulatero P., Milan A., Fallo F., et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006, 91(7):2618-2623.
111. Rossi G.P., Pitter G., Miotto D. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not?. J Hypertens 2007, 25:481-484.
112. Rossi G.P., Pitter G., Miotto D. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? Round 2. J Hypertens 2007, 25:1518-1520.
113. Hogan M.J., McRae J., Schambelan M., et al. Location of aldosterone-producing adenomas with 131I-19-iodocholesterol. N Engl J Med 1976, 294:410-414.
114. Nomura K., Kusakabe K., Maki M., et al. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab 1990, 71:825-830.
115. Mansoor G.A., Malchoff C.D., Arici M.H., et al. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 2002, 15:459-464.
116. Toniato A., Bernante P., Rossi G.P., et al. Laparoscopic versus open adrenalectomy: outcome in 35 consecutive patients. Int J Surg Investig 2000, 1:503-507.
117. Jeschke K., Janetschek G., Peschel R., et al. Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results. Urology 2003, 61:69-72.
118. Meria P., Kempf B.F., Hermieu J.F., et al. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol 2003, 169:32-35.
119. Lumachi F., Ermani M., Basso S.M., et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 2005, 71:864-869.
120. Obara T., Ito Y., Okamoto T., et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 1992, 112:987-993.
121. Proye C.A., Mulliez E.A., Carnaille B.M., et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?. Surgery 1998, 124:1128-1133.
122. Dietz J.D., Du S., Bolten C.W., et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008, 51:742-748.